Leishmaniasis is caused by a parasite from a protozoan family, which occurs in three forms: cutaneous, cutaneous-mucosal, and visceral. The infection is transmitted to humans and other mammals, mainly by being bitten by an infected sandfly (
1). The Cutaneous form of leishmaniasis starts with a small bump (papules), which gradually enlarges and turns into scares likely to heal on their own in weeks or months, and sometimes years, imposes a heavy economic burden on society, especially in developing countries (
2). Cutaneous leishmaniasis is categorized as either rural (Zoonotic leishmaniasis as wet leishmaniasis or premature leishmaniasis), with rapid growth but mild symptoms caused by
Leishmania major, or urban (Anthroponotic leishmaniasis as late-onset dry or injured leishmaniasis), with a more prolonged course by
Leishmania tropica (
3,
4). In most cases, patients develop immunity by the natural course of the disease, and the infection is eliminated with a defined scare. Despite no complete elimination of the infection, treatment accelerates the healing process but with a compromised immunity response (
5,
6). All patients with urban cutaneous leishmaniasis (ACL), which patients transmit, should be treated to prevent the spread of the disease. However, in rural leishmaniasis (ZCL), covering the wound to prevent flies from access to the contagious wound is very important and sufficient to prevent the infection’s spread. The therapeutic goals of CL are: (i) 100% recovery of patients, (ii) prevention of lesion spread mainly in the face, (iii) control of the disease reservoirs, and iv) prevention of complications such as secondary infection, lymphangitis, and prevention of disease recurrence (
7). The social stigma caused by the scares causes many psychological problems in the patients. For example, people with CL scares encounter social limitations in Afghanistan and Colombia (
8,
9). World Health Organization has announced the family of leishmaniasis infections as one of the six most important tropical and semi-tropical infections worldwide (
10,
11). Based on the reports, leishmaniasis is endemic in 98 countries (
12). In addition, it is estimated that about 350 million people are at risk of catching the infection, causing 70,000 deaths (
13). About 90% of the world's cutaneous leishmaniasis (CL) is reported in Afghanistan, Brazil, Iran, Peru, Saudi Arabia, and Syria (
14). About 30,000 new cases are reported annually in Iran, which is considered times more significant (
15). Marvdasht is one of the foci of
Leishmania in Iran. This is the first study in Iran that simultaneously examines active and old scars in the population to investigate people at risk of contracting the disease in the future and the possibility of epidemics and pandemics.